A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
People also ask
What is the life expectancy of someone with BRCA1?
Are the BRCA1 and BRCA2 genes associated with an increased risk of ovarian cancer?
What is the survival rate for BRCA2 breast cancer?
What cancer is associated with mutations of the BRCA1 gene?
Abstract. Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer.
Jun 22, 2012 · Women who carry mutations in BRCA1 or BRCA2 are at a substantially increased risk of developing breast and/or ovarian cancers. Lifetime risks ...
The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and ...
Dec 6, 2012 · Correction: A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 ...
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. / Ding, Yuan ...
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer ...
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. YC Ding ...
SWE-BRCA. / A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. / Ding, Yuan ...